Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia

D Bergeron; ML Gorno-Tempini; GD Rabinovici; MA Santos-Santos; W Seeley; BL Miller; Y Pijnenburg; MA Keulen; C Groot; BNM van Berckel; WM van der Flier; P Scheltens; JD Rohrer; JD Warren; JM Schott; NC Fox; R Sanchez-Valle; O Grau-Rivera; E Gelpi; H Seelaar; JM Papma; JC van Swieten; JR Hodges; CE Leyton; O Piguet; EJ Rogalski; MM Mesulam; L Koric; K Nora; J Pariente; B Dickerson; IR Mackenzie; GYR Hsiung; S Belliard; DJ Irwin; DA Wolk; M Grossman; M Jones; J Harris; D Mann; JS Snowden; P Chrem-Mendez; IL Calandri; AA Amengual; C Miguet-Alfonsi; E Magnin; G Magnani; R Santangelo; V Deramecourt; F Pasquier; N Mattsson; C Nilsson; O Hansson; J Keith; M Masellis; SE Black; JA Matías-Guiu; MN Cabrera-Martin; C Paquet; J Dumurgier; M Teichmann; M Sarazin; M Bottlaender; B Dubois; CC Rowe; VL Villemagne; R Vandenberghe; E Granadillo; E Teng; M Mendez; PT Meyer; L Frings; A Lleó; R Blesa; J Fortea; SW Seo; J Diehl-Schmid; T Grimmer; KS Frederiksen; P Sánchez-Juan; G Chételat; W Jansen; RW Bouchard; RJ Laforce; PJ Visser; R Ossenkoppele

Journal article

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia

D Bergeron, ML Gorno-Tempini, GD Rabinovici, MA Santos-Santos, W Seeley, BL Miller, Y Pijnenburg, MA Keulen, C Groot, BNM van Berckel, WM van der Flier, P Scheltens, JD Rohrer, JD Warren, JM Schott, NC Fox, R Sanchez-Valle, O Grau-Rivera, E Gelpi, H Seelaar Show all

Annals of Neurology | WILEY | Published : 2018

DOI: 10.1002/ana.25333

Download PDF

Abstract

Objective: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. Methods: We conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipopro..

View full abstract

University of Melbourne Researchers

Christopher Rowe Author

Victor Villemagne Author

Grants

Awarded by National Institute on Aging

Funding Acknowledgements

This work was funded by a Vanier Graduate Scholarship of the Canadian Institutes of Health Research. The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research Trust, and The Wolfson Foundation. This work was supported by the NIHR Queen Square Dementia Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility as well as an Alzheimer's Society grant (AS-PG-16-007). JDR is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH). Dr. E.J.R. was supported by the following grants acknowledged: R01 NS075075, P30 AG13854, R01 DC008552, R01 AG056258. We thank patients and families for their dedication to research.